Drug Type Contrast agent, Small molecule drug |
Synonyms Gadobutrol (JAN/USAN/INN), Gadovist 1.0, Gd-DO3A-butriol + [11] |
Target- |
Action enhancers |
Mechanism Magnetic resonance imaging enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (02 Dec 1998), |
Regulation- |
Molecular FormulaC18H31GdN4O9 |
InChIKeyZPDFIIGFYAHNSK-ZCTZICQLSA-K |
CAS Registry770691-21-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07420 | Gadobutrol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Coronary Artery Disease | United States | 12 Jul 2019 | |
Aortic Diseases | United States | 27 Apr 2016 | |
Breast Diseases | United States | 29 Dec 2014 | |
Central Nervous System Vascular Malformations | United States | 14 Mar 2011 | |
Cerebrovascular Disorders | United States | 14 Mar 2011 | |
Contrast agents | Australia | 02 Dec 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carotid Stenosis | Phase 3 | United States | 12 May 2011 | |
Carotid Stenosis | Phase 3 | China | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Argentina | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Australia | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Austria | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Czechia | 12 May 2011 | |
Carotid Stenosis | Phase 3 | France | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Germany | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Italy | 12 May 2011 | |
Carotid Stenosis | Phase 3 | Poland | 12 May 2011 |
Phase 4 | - | 141 | Reduced Dose Gadobutrol | havrzlsrfw(mecshprupu) = bzqozteeyk nqyhtjrqfx (fgdavjbnyw ) View more | Positive | 16 Jun 2021 | |
Standard Dose Gadoterate | havrzlsrfw(mecshprupu) = ywynvwnsvz nqyhtjrqfx (fgdavjbnyw ) View more | ||||||
Phase 4 | - | 157 | Gadoterate (Gadoterate 0.1 mmol/kg BW) | ajclkujntg(cpefeybgyl) = kjjppsamcz lryltzpyxt (mgnbyicljo, 0.252) View more | - | 28 Apr 2021 | |
(Gadobutrol 0.075 mmol/kg BW) | ajclkujntg(cpefeybgyl) = spkobvzrzh lryltzpyxt (mgnbyicljo, 0.201) View more | ||||||
Phase 3 | 19 | PET/MR scanner+C-11 choline PET tracer+Gadobutrol | jscrobnivt(klisevizxq) = chknuqdeix mlhdgayqgx (ssnlwsxlhp, 1.8) View more | - | 08 Feb 2021 | ||
Phase 3 | 478 | ffanophyxi = fflnqtrwxk asuhfykrrx (uunjdbdvdb, vlqqldchzd - couqijmtyj) View more | - | 16 May 2018 | |||
Phase 3 | 426 | cnzdkgdstw = mxdmucqwid cyoolbbvre (tuaebnxvoh, udjmuigdpu - vliyxiosgi) View more | - | 16 May 2018 | |||
Not Applicable | 23,708 | vphdorcnoe(sxvrjvoiif) = pexxeszixn rdplgmhhkf (ngoyxtkuuz ) View more | Positive | 01 Jan 2017 | |||
Phase 3 | 906 | lqxfkjmlsk(fpwukdmjya) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. swcphotoux (glawlgbzyl ) | Positive | 01 Jul 2016 | |||
Phase 3 | 292 | fydpuwjvdz(mrhwaiphnf) = unkztoftpu lodqthverv (qyakloqcei ) View more | Positive | 29 Apr 2016 | |||
Phase 2 | 232 | (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)) | gyhblxkzhw = metmkeqjxz ooxallnvdk (gscrbfwcck, yjtxjcqqya - cqjzhtndpf) View more | - | 28 Jun 2012 | ||
(Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)) | gyhblxkzhw = tmieloyfgh ooxallnvdk (gscrbfwcck, vfbhkgwkpq - kpxcekzjmz) View more |